UCB SA (EBR: UCB)

Belgium flag Belgium · Delayed Price · Currency is EUR
186.60
+1.80 (0.97%)
Dec 20, 2024, 5:37 PM CET
144.63%
Market Cap 35.40B
Revenue (ttm) 5.45B
Net Income (ttm) 240.00M
Shares Out 189.72M
EPS (ttm) 1.22
PE Ratio 152.72
Forward PE 32.41
Dividend 1.36 (0.73%)
Ex-Dividend Date n/a
Volume 540,704
Open 183.90
Previous Close 184.80
Day's Range 179.20 - 186.60
52-Week Range 75.98 - 190.20
Beta 0.36
Analysts n/a
Price Target n/a
Earnings Date Feb 27, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1925
Employees 9,083
Stock Exchange Euronext Brussels
Ticker Symbol UCB
Full Company Profile

Financial Performance

In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.

Financial Statements

News

United Community Banks to acquire ANB Holdings in an all-stock deal

Financial holding company United Community Banks (UCB) is set to acquire ANB Holdings, and the unit American National Bank, in an all-stock transaction.

18 days ago - Seeking Alpha

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

On Tuesday, UCB SA (OTC: UCBJY) (OTC: UCBJF) and Biogen Inc. (NASDAQ: BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ery...

4 weeks ago - Benzinga

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

On Wednesday, the FDA approved UCB SA’s (OTC: UCBJY) (OTC: UCBJF) Bimzelx (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only ...

4 weeks ago - Benzinga

United Community Banks: Too Rich For My Blood

United Community Banks' balance sheet shows mixed results in deposits and debt. Read more to see why I think UCB stock is a sell.

5 weeks ago - Seeking Alpha

Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more about UCBJF stock here.

2 months ago - Seeking Alpha

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR5...

3 months ago - Benzinga

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Responder analyses demonstrated that approximately nine out of 10 patients treated with BIMZELX who achieved PASI90 at Year 1, and over seven out of 10 patients who achieved complete skin clearance (P...

3 months ago - Benzinga

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial

3 months ago - MarketWatch

Biogen, UCB mark late-stage trial win for autoimmune disease therapy

Biogen (BIIB) and UCB (UCBJY) announce a Phase 3 trial win for an experimental therapy targeting Systemic Lupus Erythematosus (SLE). Read more here.

3 months ago - Seeking Alpha

UCB gets expanded FDA approval for psoriasis drug Bimzelx

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ankylosing spondylitis, and nr-axSpA. Read more here.

3 months ago - Seeking Alpha

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies

European biopharmaceutical company UCB SA (OTC: UCBJF) (OTC: UCBJY) announced a $680 million strategic divestment deal in China. The transaction involves the sale, divestment, and license of UCB’s m...

4 months ago - Benzinga

Abu Dhabi fund Mubadala invests in UCB Pharma's China carve-out

The sovereign fund partners with Asia's healthcare investor to acquire 100% in the carve-out

4 months ago - Zawya

Belgium's UCB to sell China neurology and allergy business for $680 mln

UCB, a Belgian biopharmaceutical firm, said on Monday that it will sell its Chinese neurology and allergy business to asset management group CBC and Abu Dhabhi's Mubadala for $680 million.

4 months ago - Reuters

Mubadala co-invests in UCB's mature business in China to reinforce its long-term commitment to the Asian market

The transaction remains subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions, and is expected to close in Q4 2024

4 months ago - Zawya

United Community Banks: Preferred Share Downgrade On Low Yield

United Community Banks has seen changes in business due to rising interest rates, but net interest income remains strong. Learn more about UCB stock here.

4 months ago - Seeking Alpha

UCB SA (UCBJF) Q2 2024 Earnings Call Transcript

UCB SA (OTCPK:UCBJF) Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Antje Witte - Head, IR Jean-Christophe Tellier - CEO Sandrine Dufour - CFO Emmanuel Caeymaex - CCO I...

5 months ago - Seeking Alpha

UCB SA (UCBJF) Full Year 2023 Earnings Call Transcript

UCB SA (OTCPK:UCBJF) Full Year 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Antje Witte – Investor Relations Jean-Christophe Tellier – Chief Executive Officer Emmanu...

10 months ago - Seeking Alpha